Kura Oncology (KURA) Total Liabilities (2010 - 2026)

Kura Oncology (KURA) has 17 years of Total Liabilities data on file, last reported at $544.7 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $544.7 million, up 43.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $544.7 million (up 43.58% YoY), and the FY2025 annual result was $564.2 million, up 62.83% from the prior year.
• Total Liabilities eased to $544.7 million in Q1 2026 per KURA's latest filing, from $564.2 million in the prior quarter.
• Over five years, Total Liabilities peaked at $564.2 million in Q4 2025 and troughed at $21.9 million in Q2 2022.
• A 5-year average of $178.9 million and a median of $49.0 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Liabilities tumbled 34.84% in 2022, then soared 676.99% in 2025.
• A 5-year view of Total Liabilities shows it stood at $36.0 million in 2022, then jumped by 43.39% to $51.7 million in 2023, then surged by 570.74% to $346.5 million in 2024, then soared by 62.83% to $564.2 million in 2025, then decreased by 3.47% to $544.7 million in 2026.
• Business Quant data shows KURA's Total Liabilities at $544.7 million in Q1 2026, $564.2 million in Q4 2025, and $406.8 million in Q3 2025.